Leerink Partners analyst Michael Cherny has reiterated their bullish stance on LH stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Cherny has given his Buy rating due to a combination of factors that highlight Labcorp Holdings’ strategic growth initiatives. The company’s recent acquisition of laboratory assets from Community Health Systems aligns with its successful strategy of purchasing laboratory assets, which has historically resulted in strong returns on investment. This acquisition is expected to contribute to incremental growth from fiscal year 2026 onwards, indicating a prudent use of capital.
Additionally, Labcorp’s balanced approach to mergers and acquisitions, including its deal with Invitae, complements its stable organic growth trajectory. This strategic focus on acquiring assets that offer significant cost reduction opportunities supports the company’s overall growth outlook. Cherny reiterates an Outperform rating, anticipating solid results in the upcoming earnings report.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $285.00 price target.
LH’s price has also changed slightly for the past six months – from $242.450 to $252.070, which is a 3.97% increase.